MAPT and supranuclear palsy, progressive, 1: Despite the large number of studies assessing the diagnostic potential of phosphorylated tau species for diagnosing Alzheimer’s disease [3], very few studies evaluated these biomarkers in peripheral fluids in PSP, with few data restricted to p-tau181 in plasma [18,19,20,21] and serum [22].